nach oben

Erschienen in:

01.12.2012 | Research Article

Study of KRAS new predictive marker in a clinical laboratory

verfasst von: Inmaculada Bando, Lourdes Cillero, Julián Sanz-Ortega, Patricia Llovet, Paula Pescador, Milagros Ferrer, Miguel de la Hoya, Javier Sastre, Eduardo Díaz-Rubio García, Trinidad Caldés

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The presence of somatic mutations in the KRAS gene has been identified as a reliable strong negative predictor for the response to targeting the epidermal growth factor receptor (EGFR), in patients with metastatic colorectal cancer and the use of anti-EGFR monoclonal antibodies such as Cetuximab and Panitumumab is now restricted to patients with no detectable KRAS mutations. Between 30 and 40 % of colorectal cancers contain a mutated KRAS oncogene. The aim of this study was to evaluate concordance between three methods to analyze KRAS mutational status in regard to clinical testing.

Methods

We analyzed KRAS mutations in codons 12 and 13 of exon 2 in one hundred formalin-fixed paraffin-embedded (FFPE) colorectal cancer samples by three different methods: Direct Sequencing and two commercial kits on allele-specific oligonucleotide hybridization (KRAS StripAssay, Vienna Lab.) and Amplification Refractory Mutation System/Scorpions (ARMS/S; TheraScreen KRAS Mutation kit DxS) based on q-PCR.

Results

We have found similar frequencies of KRAS mutations by TheraScreen and Strip-Assay (44 and 48 %), with a κ value of 0.90, indicating almost perfect agreement between methods. The frequency by direct sequencing was much lower (26 %) and the κ values were 0.67 (compared to TheraScreen) and 0.57 (compared to Strip-Assay) indicating low sensitivity.

Conclusions

On analyzing KRAS mutation in FFPE tumor samples, direct sequencing sensitivity is too low to be used in a clinical setting. Choosing between ARMS/S; TheraScreen KRAS Mutation kit DxS and KRAS StripAssay, Vienna Lab, will depend on laboratory facilities and expertise.

Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779–827PubMedCrossRef

Grady WM, Markowitz SD (2002) Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3:01–128CrossRef

Allegra CJ, Jessup JM, Somerfield MR, Halminton SR, Hammond EH, Hayes DF et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096PubMedCrossRef

Gallegos Ruiz MI, Floor K, Rijmen F, Grünberg K, Rodriguez JA (2007) EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 29:257–264

Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ et al (2010) A comparability study of 5 commercial KRAS tests. Diagn Pathol 5:23

Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N et al (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503–2516PubMedCrossRef

Thelwell N, Millington S, Solinas A, Booth J, Brown T (2000) Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 28:3752–3761PubMedCrossRef

Angulo B, García-García E, Martínez R, Suárez-Gauthier A, Conde E, Saletti P, Hidalgo M et al (2010) A commercial real-time PCR kit provides greater sensitivity tan direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol diagn JMC 12:292–299CrossRef

Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S et al (2009) Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 11:508–513PubMedCrossRef

10.

Viera AJ, Garrett JM (2005) Understanding inter observer agreement: the kappa statistic. Fam Med 37:360–363PubMed

11.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2:5705–2712

12.

Hirsch FR, Bunn PA Jr (2009) EGFR testing in lung cancer is ready for prime time. Lancet Oncol 0:432–433CrossRef

13.

Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379PubMedCrossRef

14.

Liévre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995PubMedCrossRef

15.

Karapetis CS, Khambata-Ford S, Jonker DJ, O′Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 359:1757–1765PubMedCrossRef

16.

De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515PubMedCrossRef

17.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRef

18.

Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C et al (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7:413–421PubMedCrossRef

19.

Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R et al (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130:247–253PubMedCrossRef

20.

Clayton SJ, Scott FM, Walker J, Callghan K, Haque K, Liloglou T, Field JK, Fox JC et al (2000) K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 46:1929–1938PubMed

21.

Nollau P, Wagener C (1997) Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques. Clin Chem 43:1114–1128PubMed

22.

Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature reviews. Clin Oncol 6:519–527

23.

Martínez F, Fernández-Martos C, Quintana MAJ, Castell A, Llombart A, Iñiguez F, Guillem V, Dasi F (2011) APC and KRAS mutations in distal colorrectal polyps are related to smoking habits in men: results of a cross-sectional study. Clin Transl Oncol 13:664–671PubMedCrossRef

Titel: Study of KRAS new predictive marker in a clinical laboratory
verfasst von: Inmaculada Bando
Lourdes Cillero
Julián Sanz-Ortega
Patricia Llovet
Paula Pescador
Milagros Ferrer
Miguel de la Hoya
Javier Sastre
Eduardo Díaz-Rubio García
Trinidad Caldés
Publikationsdatum: 01.12.2012
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0886-z

Springer Medizin

Study of KRAS new predictive marker in a clinical laboratory